The Healing
Question

In the spring of 1991, a team of Croatian researchers published a paper in the journal European Journal of Pharmacology describing a peculiar fragment of a human growth hormone. They had isolated a 15-amino-acid chain — a peptide — and observed something unexpected: when administered to rats with perforated stomachs and transected quadriceps muscles, wounds closed faster. Angiogenesis increased. Tendons regrew. The paper was meticulous and largely ignored.

That peptide, now known as BPC-157, has spent three decades in scientific purgatory — banned by regulators, embraced by athletes, studied in small trials abroad, and almost completely overlooked by American pharma. Today it is the subject of more Reddit posts than PubMed-indexed studies, a compound that has achieved a rare status in modern medicine: genuine enthusiasm among patients, widespread skepticism among physicians, and a quiet but growing body of mechanistic research that deserves a more careful look.

What BPC-157 Actually Is

BPC stands for "Body Protection Compound." The number 157 refers to its position in the sequence of human growth hormone. The compound is a synthetic fragment — it does not occur in nature. Its proponents claim it promotes healing through a cascade of mechanisms: upregulating growth hormone receptors, promoting angiogenesis (new blood vessel formation), modulating nitric oxide pathways, and stabilizing the gastrointestinal lining.

Researchers at the University of Zagreb, where much of the early work was conducted, describe BPC-157 as a "stable gastric pentadecapeptide" — a description that is both accurate and unhelpful to anyone outside a biochemistry lab. In plain terms: it's a short chain of amino acids, structurally stable enough to survive the digestive tract, capable of interacting with multiple biological pathways simultaneously.

The Evidence, Such As It Is

The scientific record on BPC-157 is unusual in structure. There is a dense body of animal research — mouse and rat studies spanning wound healing, tendon repair, bone healing, and neuroprotection. These studies are reproducible and consistent. The effect sizes are striking. A 2019 paper in Frontiers in Pharmacology described BPC-157 accelerating the healing of Achilles tendon transection in rats by nearly 50% compared to controls.

What is conspicuously absent is Phase II human trials. No large-scale clinical trials. No FDA approval. No pharmaceutical company has brought BPC-157 through the regulatory process. This is not unusual for a compound that cannot be patented — which is the case for any short amino acid sequence that occurs naturally in the body. Without patent protection, there is no financial incentive to fund the tens of millions of dollars required for FDA approval. The compound exists in a regulatory gray zone: not a drug, not a supplement, not a food — a research chemical of sorts, produced by compounding pharmacies and sold in a gray market.

Why Athletes Are Talking About It

The anecdotal literature is extensive. A 2024 survey of online peptide forums — a methodology that would make any epidemiologist wince — found that BPC-157 was among the most frequently discussed compounds for musculoskeletal injuries. Bodybuilders recovering from distal biceps tears. Weekend warriors returning from ACL reconstruction. Rugby players with chronic Achilles tendinopathy. The reports are uniformly enthusiastic.

"It was the only thing that got my golfer's elbow to resolve before surgery was my only option." — Forum user, r/Peptides, 2024

The problem with this evidence is not that it's fabricated — it's likely not — but that it is uncontrolled, unblinded, and subject to the well-documented psychological phenomenon of treatment effect in musculoskeletal medicine. Healing is nonlinear. Time passes. Rest helps. Tendons heal. It is nearly impossible, in a single case, to distinguish drug effect from natural history.

The Safety Question

Here the picture is more reassuring than expected. The acute toxicity profile of BPC-157 appears remarkably clean. Doses up to 10μg/kg in rats produced no observable adverse effects. No significant drug-drug interactions have been documented. The compound does not appear to be carcinogenic or teratogenic. This is not the same as "safe in humans" — the dose-response relationship has not been established, and chronic use has not been studied — but it is not nothing.

The More Interesting Question

The real story with BPC-157 is not whether it works — the animal data is consistent enough that it almost certainly does something — but why the mechanism is so poorly understood, and what the existence of such a compound tells us about the limits of our current approach to musculoskeletal medicine.

We have excellent surgical interventions and excellent rehabilitation protocols. We have NSAIDs and corticosteroids. What we do not have is a reliable pharmacologic tool for accelerating tissue healing. Physical therapy works — but it works slowly, and compliance is a real problem. Surgical repair works — but it is invasive, expensive, and requires weeks of immobilization. If a peptide could meaningfully accelerate tendon healing without surgery, the clinical need is obvious.

BPC-157 may or may not be that peptide. But its existence — and the intensity of interest it has generated — is a signal that the market for this need is large and largely unmet. The researchers in Zagreb did not set out to create the next great biohacking compound. They were trying to understand how the stomach heals. The fact that what they found might also heal Achilles tendons is either a remarkable coincidence or a hint about the deep generality of the mechanism.

We'll know more when the first serious human trials report. Until then, BPC-157 remains a compound that looks extraordinarily promising in animals, is almost certainly being used by a meaningful fraction of serious athletes, and is almost entirely unknown to the physicians who treat the injuries it might help.

If you've spent any time in the corners of the internet where longevity enthusiasts and performance optimizers gather, you've encountered peptides. The word is used constantly and, more often than not, incorrectly. So let's start with the definition that matters: a peptide is a short chain of amino acids, linked together by peptide bonds, that folds into a specific three-dimensional shape — a shape that determines what it does.

That's it. That's the whole concept.

From Amino Acid to Bioactive Molecule

The human body contains roughly 20 amino acids. Chain two of them together, you have a dipeptide. Chain three, a tripeptide. Chain ten, a oligopeptide. Chain fifty or more, and you have a protein. Peptides sit in the sweet spot: short enough to be synthesized and administered as discrete molecules, long enough to fold into structures complex enough to interact specifically with biological targets.

Consider insulin. It is a peptide hormone — 51 amino acids, two chains, folded into a precise 3D shape that allows it to bind the insulin receptor with extraordinary specificity. Before recombinant DNA technology made bacterial production possible, insulin was extracted from pig and cow pancreases. The molecule is small enough that its structure can be fully characterized, reproduced, and modified. This is why peptide drugs are relatively easy to develop and manufacture — compared to large proteins like antibodies, they are small, stable, and chemically tractable.

How Peptides Work in the Body

Peptides function primarily as signaling molecules. They bind to specific receptors — on cell surfaces, in the cytoplasm, sometimes in the nucleus — and trigger downstream cascades. The specificity of binding is determined by the peptide's amino acid sequence and its 3D conformation, which together determine which receptors it can engage.

This is why small modifications to a peptide sequence can have dramatic effects. Substituting one amino acid for another can change binding affinity, half-life, stability, and biological activity. The pharmaceutical industry has spent decades learning to do this precisely — to take a naturally occurring peptide and optimize it for therapeutic use. This is how semaglutide was developed from the gut hormone GLP-1: by understanding the native sequence, identifying which modifications would increase stability and half-life, and engineering a better version.

"Every peptide in your body is a solution to an evolutionary problem. We're just now learning to read and modify those solutions."

Why Peptides Are Different from Small-Molecule Drugs

Most drugs are small molecules — aspirin, ibuprofen, metformin. These are typically under 500 Daltons in molecular weight, can be taken orally, and are metabolized relatively quickly. Peptides are larger, typically 500 to 5,000 Daltons. They are usually not orally bioavailable (they get digested in the GI tract), which means they must be injected or, increasingly, administered via other routes that bypass the gut.

This is a genuine limitation. But it comes with a compensating advantage: peptide drugs are extraordinarily specific in their targets. Small molecules often bind to multiple receptor types, producing off-target effects. Peptides, because of their precise 3D geometry, tend to bind one receptor — or one family of receptors — and almost nothing else.

The Pipeline Problem

There are over 100 FDA-approved peptide drugs on the market. Insulin. Semaglutide. GLP-1 agonists. Oxytocin. Leuprolide. The list is long and growing. The barrier to entry is not synthesis — peptide manufacturing is now relatively inexpensive — but regulatory approval, which requires clinical trials and patent protection. As a result, many naturally occurring peptides with therapeutic potential sit in a purgatory of underdevelopment, unable to attract the investment needed to clear regulatory hurdles.

This is why compounding pharmacies play a significant role in the peptide ecosystem. They are legally permitted to compound individualized preparations of FDA-approved drugs — and, in a legal gray zone, to produce peptides that are not scheduled substances. The result is a parallel market where physicians can prescribe, and patients can obtain, peptide formulations that have not been through the FDA approval process.

Whether this is a failure of regulation or a reasonable accommodation for a legitimate medical need depends on your priors. What is not in dispute is that it exists, and that the patients who use these compounds are not, on the whole, being defrauded — the molecules they're receiving are what they claim to be. The question is whether the clinical use is supported by sufficient evidence. In many cases, it is not yet clear that it is.

Understanding peptides — what they are, how they work, what the evidence does and does not support — is increasingly a prerequisite for informed participation in modern medicine. The molecules are not magic. They are tools, and like all tools, their value depends on the skill with which they're used and the conditions under which they're deployed.

On a Tuesday morning in a strip mall outside Houston, a pharmacist named Chen — he asked that his last name not be used — is working a vial of white powder into solution. The powder is BPC-157, 10mg, manufactured in China, purchased from a supplier he has used for four years. He will combine it with bacteriostatic water, draw it into 1ml vials, and ship it to a clinic in Arizona that treats athletes with chronic tendinopathy.

This is the peptide supply chain in the United States: fragmented, largely invisible, and operating in the space between FDA-regulated pharmaceuticals and outright gray market production. Understanding it requires understanding what compounding pharmacies are, what they're permitted to do, and how those rules shape what peptides are available and to whom.

The Basics of Compounding

A compounding pharmacy is, in essence, a custom pharmacy. Instead of dispensing mass-manufactured pills and injectables, it prepares individualized formulations for specific patient needs. A child who can't swallow pills might get a liquid suspension. A patient with a dye allergy might get a preservative-free version. Compounding is a legitimate and important part of pharmaceutical care — and it is also the legal gateway through which most peptide products enter the US market.

The Food, Drug, and Cosmetic Act creates a distinction between conventional drugs (manufactured under FDA approval) and compounded drugs (prepared by pharmacies under state law, exempt from FDA approval requirements). For years, this distinction was relatively clean. Then the peptide boom changed things.

"Before 2020, we maybe had a few dozen peptide patients. Now it's hundreds. We're doing peptide consultations as a standard service."

The pharmacist is describing a real shift. Compounding pharmacies that once specialized in hormone replacement therapy have expanded aggressively into peptides — not just BPC-157, but TB-500, CJC-1295, Ipamorelin, DSIP, and a growing list of compounds with acronyms and names that would be unrecognizable to anyone outside a sports medicine clinic.

What Is Made, and How

The manufacturing process for most peptides follows a standard protocol. Raw active pharmaceutical ingredient (API) — the peptide powder — is synthesized by contract manufacturers, primarily in China and India, using solid-phase peptide synthesis (SPPS). The powder is then shipped to compounding pharmacies, which dissolve it in solution, filter it for sterility, and divide it into vials or pre-loaded syringes.

The quality of the raw material varies. Reputable compounding pharmacies test each batch for purity, identity, and potency using high-performance liquid chromatography (HPLC) and mass spectrometry. Less reputable operations may not. The FDA has issued warning letters to compounding pharmacies for quality control failures, including contamination and incorrect concentrations.

At Chen's pharmacy, I observed the testing process. Each batch of BPC-157 received a certificate of analysis from the supplier. Chen's team ran its own HPLC verification before compounding. "We don't take their word for it," he said. "We're liable."

The Prescribing Equation

The availability of peptides from compounding pharmacies depends on a second variable: physician willingness to prescribe. In most states, a licensed physician must write a prescription for a compounded peptide preparation. This creates a clinical gate — a physician must evaluate the patient, determine that a peptide is clinically indicated, and write the prescription.

In practice, the prescription requirement is loosely enforced for peptides in some clinics. There are "peptide clinics" — many of them operating as telemedicine services — that offer consultations and prescribe peptide regimens with minimal clinical workup. The clinical standard here is variable. Some clinics are run by physicians who are genuinely engaged with the literature. Others are running a volume business with thin clinical oversight.

Chen's pharmacy requires a valid prescription before dispensing. "We're not going to sell to a patient who just wants to try it," he said. "We're not going to sell to a clinic that doesn't have a real physician reviewing cases." His tone was firm. "There are pharmacies that will. I'm not saying that to throw anyone under the bus. I'm saying it because it matters."

The Regulatory Horizon

The FDA has been attentive to the peptide space, if not always effectively. In 2023, the agency issued guidance clarifying that bulk peptide APIs — the raw powder used by compounders — are not exempt from the drug approval process when sold for compounding. The guidance created significant uncertainty in the industry and triggered a round of consolidation as smaller operations either came into compliance or shut down.

Whether this leads to more rigorous standards or simply pushes production further into the gray market remains to be seen. The underlying demand is real — athletes, aging adults, people with chronic injuries — and it is not going away. The regulatory question is not whether to serve this demand but how.

Chen was philosophical about the future. "We're operating in a space where the rules haven't caught up with the technology," he said, capping a vial and setting it aside for QC. "That used to bother me more than it does now. Eventually they catch up. Until then, we do the work correctly and let the results speak."

It's not a satisfying answer for anyone who wants clear rules. But it is, for the moment, an accurate one.